Filtered By:
Cancer: Colorectal Cancer

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 198 results found since Jan 2013.

Loss-of-Function in SMAD4 Might Not Be Critical for Human Natural Killer Cell Responsiveness to TGF- β
This study was carried out in accordance with approval of the Melbourne Health and Walter and Eliza Hall Institute of Medical Research's Human Research Ethics Committee (approval number: 2013.081). All subjects gave written informed consent for participation and publication. Results and Discussion TGF-β signaling in NK cells is associated with: phosphorylation in SMAD2 and 3, inhibition of IL-15-induced metabolism/proliferation, simultaneous downregulation of CD44, CD49e, and Eomes, and upregulation of CD16 and CD49a expression (7, 10). SMAD family member 4 (SMAD4) belongs to the SMAD family of transcript...
Source: Frontiers in Immunology - April 30, 2019 Category: Allergy & Immunology Source Type: research

Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research

Role of Mast Cells in Shaping the Tumor Microenvironment
AbstractEarly mast cell (MC) infiltration has been reported in a wide range of human and animal tumors particularly malignant melanoma and breast and colorectal cancer. The consequences of their presence in the tumor microenvironment (TME) or at their margins still remain unclear as it is associated with a good or poor prognosis based on the type and anatomical site of the tumor. Within the tumor, MC interactions occur with infiltrated immune cells, tumor cells, and extracellular matrix (ECM) through direct cell-to-cell interactions or release of a broad range of mediators capable of remodeling the TME. MCs actively contri...
Source: Clinical Reviews in Allergy and Immunology - June 28, 2019 Category: Allergy & Immunology Source Type: research

The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta ‐analysis of patient and study characteristics
ConclusionsIRs occur in approximately 5% of mCRC patients treated with anti ‐EGFR therapies, and the incidence varies significantly by grade of severity and therapy type. Studies evaluating these outcomes should consider investigating survival outcomes by IR status to determine its prognostic relevance.
Source: Cancer Medicine - August 2, 2019 Category: Cancer & Oncology Authors: Lauren C. Bylsma, Rebecca Dean, Kimberly Lowe, Laura Sangar é, Dominik D. Alexander, Jon P. Fryzek Tags: ORIGINAL RESEARCH Source Type: research

Methanogenic Archaea: Emerging Partners in the Field of Allergic Diseases
AbstractArchaea, which form one of four domains of life alongside Eukarya, Bacteria, and giant viruses, have long been neglected as components of the human microbiota and potential opportunistic infectious pathogens. In this review, we focus on methanogenic Archaea, which rely on hydrogen for their metabolism and growth. On one hand, methanogenic Archaea in the gut are functional associates of the fermentative digestion of dietary fibers, favoring the production of beneficial short-chain fatty acids and likely contributing to the weaning reaction during the neonatal window of opportunity. On the other hand, methanogenic Ar...
Source: Clinical Reviews in Allergy and Immunology - September 13, 2019 Category: Allergy & Immunology Source Type: research

Immune Overdrive Puts Some Colorectal Cancer Patients at Risk for Poor Outcomes Immune Overdrive Puts Some Colorectal Cancer Patients at Risk for Poor Outcomes
Immune cell infiltration of tumors is usually associated with favorable outcomes, but sometimes in colorectal cancer (CRC) the opposite is true, researchers say. They caution that Immunoscore, developed to predict CRC recurrence, may incorrectly classify high-risk patients as low risk.Reuters Health Information
Source: Medscape Allergy Headlines - October 8, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Lipoxygenase inhibitors as cancer chemopreventives: discovery, recent developments, and future perspectives.
CONCLUSION: This review gives insights into the novel lipoxygenase inhibitors with anticancer activity as well as the different molecular pharmacological strategies to inhibit the enzyme effectively. The findings confirm that certain groups of LO inhibitors could act as promising chemopreventive agents. PMID: 31820690 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - December 8, 2019 Category: Chemistry Authors: Mahboubi-Rabbani M, Zarghi A Tags: Curr Med Chem Source Type: research

Association between atopic dermatitis and colorectal cancer risk: A nationwide cohort study
The role of atopic dermatitis (AD) in the development of colorectal cancer (CRC) has been a matter of scientific debate with mixed results. We conducted a nationwide cohort study to assess the association between AD and risk of CRC. Drawing on Taiwan's National Health Insurance Research Database, 46,703 patients with AD (the AD cohort) and 186,812 sex, age, and index year-matched patients without AD (the non-AD cohort) were identified in the period between 2000 and 2008. Follow-up time was calculated from the date of entry in the cohort until the occurrence of a first CRC diagnosis, death, or the end of the observation per...
Source: Medicine - January 1, 2020 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Comparative Evaluation of Colon Cancer Specific Antigen-2 Test and Chromocolonoscopy for Early Detection of Egyptian Patients with Colorectal Cancer
Source: Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry - September 7, 2020 Category: Allergy & Immunology Authors: Elhossary, Marwa Hawash, Nehah Badawi, Rehab Yousef, Mohamed Abd-Elsalam, Sherief Elhendawy, Mohammed Wasfy, Rania Abou-Saif, Sabry ElBendary, Amal Ismail, Saber Tags: Research article Source Type: research

Guidelines Suggesting Children Avoid Plant-Based Milks: A Closer Examination
AbstractRecentHealthy Drinks, Healthy Kids (HDHK) guidelines state children between 12 and 24  months need to be consuming 2–3 cups a day of whole fat cow’s milk, and less of all other beverages except water. Guidelines explicitly state plant-based milks should be avoided (with the exception of soy milk). We agree that in the first 12 months the optimal food for childhood growth is bre ast milk, with formula used where needed. However, after weaning, milk of any kind is not required, and should not be relied upon as a main source of calories. Children will be fine with water and a healthy balanced diet. Whether cow...
Source: Maternal and Child Health Journal - September 8, 2020 Category: Health Management Source Type: research

Screening For Colorectal Cancer in the Age of Simulation Models: A Historical Lens
In late March, The Washington Post, citing unnamed officials, quoted Dr Anthony S. Fauci ’s response to the demands of modeling the novel coronavirus epidemic: “I’ve looked at all the models. I’ve spent a lot of time on the models. They don’t tell you anything. You can’t really rely upon models.”1 The provocative claim from the Director of the National Institute of Allergy and Infectious Diseases was quickly seized upon by critics of the Coronavirus Task Force’s recommendations. Simulation models, however, are certainly not new and have played a prominent role in epidemiology for many decades.
Source: Gastroenterology - July 15, 2020 Category: Gastroenterology Authors: Christopher J. Phillips, Robert E. Schoen Tags: Commentary Source Type: research

Successful desensitization with chemotherapeutic drugs: a Tertiary Care Center Experience
Conclusions. Desensitization is an effective and safe treatment approach for chemotherapeutic drug hypersensitivity and can be performed safely by observing general precautions to anaphylaxis.PMID:33944541 | DOI:10.23822/EurAnnACI.1764-1489.202
Source: Clinical Colorectal Cancer - May 4, 2021 Category: Cancer & Oncology Authors: M E Çakmak S B Kaya Ö C Bostan Ö Ö Aktaş E Damado ğlu G Karakaya A F Kalyoncu Source Type: research

PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: *NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news